Table 4.
Summary of studies with relatively large cohort of patients who underwent hepatectomy for liver metastasis from gastrointestinal stromal tumors
| Ref. | Year | Period | No. of patients underwent hepatectomy | MST (mo) | 3-ysr (%) | 5-ysr (%) | 3-yPFS (%) | No. of patients with TKI | Factors associated with worse overall survival |
| DeMatteo et al[26] | 2001 | 1982-2000 | 341 | 391 | 501 | 301 | 451 | NR | Interval from primary tumor diagnosis ≤ 24 mo2 |
| Nunobe et al[27] | 2005 | 1984-2003 | 18 | 36 | 64 | 34 | NR | 3 (17%) | NR |
| Xia et al[28] | 2010 | 2005 | 19 | 33 (mean) | 90 | NR | NR | 19 (100%) | Non-surgical therapy2 |
| Turley et al[29] | 2012 | 1995-2010 | 39 | Not reached at 5 yr | 68 | NR | NR | 27 (73%)3 | Non-TKI therapy, extrahepatic disease |
| Bauer et al[30] | 2014 | Until 2011 | 104 | 96 | NR | NR | NR | > 84% | Male4, R2 resection4, progression disease to TKI at the time of surgery4, extrahepatic disease4 |
| Du et al[31] | 2014 | NR | 19 | Not reached | NR | NR | 88 (2-yr) | 19 (100%) | Non-surgical therapy2 |
| Seesing et al[32] | 2016 | 1999-2014 | 48 | 90 | 80 | 76 | 67 | 42 (88%) | Margin status (R1,2) |
1
Including gastrointestinal sarcoma;
2
Copmarison to the non-operation group;
3
Excluding two patients lost to follow-up;
4
Results including resections of extrahepatic metastasis. GIST: Gastrointestinal stromal tumor; MST: Median survival time; ysr: Year survival rate; PFS: Progression-free survival; TKI: Tyrosine kinase inhibitor; NR: Not reported.